IGF-1 LR3 0.1mg

Description

IGF-1 LR3 Technical Overview

IGF-1 LR3, also known as Long R3 IGF-I, is a modified analogue of insulin-like growth factor 1.

The peptide contains an N-terminal extension and an amino acid substitution that alter its binding characteristics relative to native IGF-1.

Research has investigated IGF-1 LR3 in growth factor signaling, IGF-binding protein interactions, and cellular proliferation models.

Compound Specifications

Storage and Handling

• Follow protein-specific manufacturer storage conditions.
• Protect from moisture and contamination.
• Minimize temperature changes.

Lyophilized Format

Long R3 IGF-I may be manufactured in lyophilized form. Stability depends on formulation.

Research Use Disclaimer

IGF-1 LR3 is not FDA-approved for human therapeutic use. Not intended for human or veterinary administration.

Frequently Asked Questions

What Is IGF-1 LR3?

An extended synthetic analogue of IGF-1.

How Many Amino Acids Does It Contain?

83.

What Receptor Is Associated With It?

IGF-1R.

How Does It Differ From IGF-DES?

IGF-DES is truncated, while LR3 includes an extension and amino acid substitution.

Research Overview

Long R3 IGF-I is investigated in receptor and binding protein research.

IGF-1R Signaling

Research examines growth factor receptor activity.

Binding Protein Interactions

Experimental studies characterize altered IGFBP binding.

Cell Proliferation

Research investigates growth factor-associated cellular responses.

Research Applications

References

1. Francis GL, Ross M, Ballard FJ, et al. (1992). Novel Recombinant Fusion Protein Analogues of Insulin-Like Growth Factor-I. Publication record.

Certificate of Analysis (COA)

Documentation should confirm sequence, molecular identity, purity, and actual content.

Peptide Lives